Human MUC1 ELISA Kit (Colorimetric)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-59962
Key Product Details
Sample Type & Volume Required Per Well
Serum (50 - 100 uL)
Sensitivity
3.8 U/mL
Assay Range
15 U/mL - 250 U/mL
Product Specifications
Assay Type
Sandwich ELISA
Kit Type
ELISA Kit (Colorimetric)
Reactivity
Human
Specificity
This assay has high sensitivity and excellent specificity for detection of human CA15-3. No significant cross-reactivity or interference between human CA15-3 and analogues was observed.
Description
Assay Length: 1-5 hours
Precision
Intra-Assay Precision (Precision within an assay) %CV < 15
Inter-Assay Precision (Precision between assays) %CV < 20
Scientific Data Images for Human MUC1 ELISA Kit (Colorimetric)
ELISA: Human CA15-3 ELISA Kit (Colorimetric) [NBP2-59962]
Human MUC1 ELISA Kit (Colorimetric) [NBP2-59962] -
Human MUC1 ELISA Kit (Colorimetric) [NBP2-59962] - Standard Curve ReferenceKit Contents for Human MUC1 ELISA Kit (Colorimetric)
- Adhesive Strip (For 96 wells)
- Assay plate
- HRP-conjugate
- Instruction manual
- Sample Diluent
- Standard
- Stop Solution
- Substrate A
- Substrate B
- Wash Buffer (20 x concentrate)
Preparation and Storage
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Storage of components varies. See protocol for specific instructions.
Background: MUC-1
Overexpression of mucins, including MUC1, is a feature of many epithelial cancers (1,3,5,6). The presence of truncated glycan structures called tumor-associated carbohydrate antigens (TACAs) on MUC1 play a role in cancer progression and a loss of apical-basal polarity (5). Carbohydrate-binding partners called lectins are the primary binding partners of TACAs that give rise to the pro-tumor microenvironment and metastasis (5). Given this unique feature, TACAs are a potential target for cancer immunotherapies (5). There are a number of vaccines, drugs, and antibodies targeting MUC1 for treatment of a variety of cancers including breast, lung, and prostate (6). In addition to a role in cancer progression, MUC1, and specifically the CT portion, has been shown to have a positive, anti-inflammatory role in a variety of lung and airway infections (7).
References
1. Khodabakhsh, F., Merikhian, P., Eisavand, M. R., & Farahmand, L. (2021). Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling. Cancer cell international. https://doi.org/10.1186/s12935-021-01899-8
2. Nath, S., & Mukherjee, P. (2014). MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in molecular medicine. https://doi.org/10.1016/j.molmed.2014.02.007
3. Dhar, P., & McAuley, J. (2019). The Role of the Cell Surface Mucin MUC1 as a Barrier to Infection and Regulator of Inflammation. Frontiers in cellular and infection microbiology. https://doi.org/10.3389/fcimb.2019.00117
4. Uniprot (P15941)
5. Beckwith, D. M., & Cudic, M. (2020). Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. Seminars in immunology. https://doi.org/10.1016/j.smim.2020.101389
6. Almasmoum H. (2021). The Roles of Transmembrane Mucins Located on Chromosome 7q22.1 in Colorectal Cancer. Cancer management and research. https://doi.org/10.2147/CMAR.S299089
7. Ballester, B., Milara, J., & Cortijo, J. (2021). The role of mucin 1 in respiratory diseases. European respiratory review : an official journal of the European Respiratory Society. https://doi.org/10.1183/16000617.0149-2020
Long Name
Mucin 1, Cell Surface-associated
Alternate Names
CD227, Episialin, H23AG, KL-6, Mucin-1, PEM, PEMT
Gene Symbol
MUC1
Additional MUC-1 Products
Product Documents for Human MUC1 ELISA Kit (Colorimetric)
Product Specific Notices for Human MUC1 ELISA Kit (Colorimetric)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.
Loading...
Loading...
Loading...
Loading...